Company intelligence
Vineyard | Comprehensive GLP-1 and Obesity Care
Vineyard is a science-based virtual clinic focused on metabolic health.
About Vineyard | Comprehensive GLP-1 and Obesity Care
Vineyard is a virtual health clinic specializing in GLP-1 medicines and cardiometabolic health. We believe you can have fast and convenient care that is also comprehensive. Vineyard connects you with your own dedicated obesity doctor who will be there when you need them. Get proven medications quickly with top-quality care. ✔️ Brand Name GLP-1 Medications ✔️ Direct Physician Access ✔️ Expert Dietitian Support & Content ✔️ LiftRX Strength Program ✔️ Community Support Groups & Educational Events ✔️ Body Composition Research Serving members in all 50 US states! We are physician-owned, funded, and operated by Dr. Spencer Nadolsky. We aren't just another online pill mill. We provide whole person care and look beyond just weight— addressing nutrition, fitness, sleep, stress, blood pressure, cholesterol, and other factors affecting your health. And we're not just following the research—we're actively conducting it. We study how GLP-1 medications, exercise, and high protein affect body composition. This research aims to do more than just cause weight loss. It seeks to help patients lose fat while maintaining muscle to improve long-term health.
Verified activity
Signals from Vineyard | Comprehensive GLP-1 and Obesity Care
4 published signals
Presence & Recognition
Vineyard | Comprehensive GLP-1 and Obesity Care welcomed Dr. Nicholas Pennings to join the company to help build its own lipedema program.
Reported by Vineyard | Comprehensive GLP-1 and Obesity Care
Research & Knowledge
Vineyard | Comprehensive GLP-1 and Obesity Care published a new intervention study on patients traveling abroad, noting that anecdotally they often lose weight when spending time in Europe, Asia, or Africa.
Reported by Michael Albert MD
Research & Knowledge
Vineyard | Comprehensive GLP-1 and Obesity Care announced that Novartis missed its primary endpoint in the Lp(a)HORIZON cardiovascular outcomes trial for lipoprotein(a) with pelacarsen, which lowered Lp(a) exactly as designed.
Reported by Michael Albert MD